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Conclusion: The masseter and temporalis muscles require different pres-
sures for distinguishing masticatory myofascial pain patients from asymp-
tomatic individuals. Because the highest sensitivity (73%) and LR were
found for the anterior temporalis, this muscle was considered to have the
most suitable discriminative capacity.
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THE EFFECT OF SMALL DOSES OF BOTULINUM TOXIN ON
NECK-SHOULDER MYOFASCIAL PAIN SYNDROME
I.F. Fedotova°, V.V. Fedotov. Department of Vertebrology, Sytenko
Institute of Spine and Joint Patology/Kharkov, Ukraine
Objectives: The aim of this work was to determine the effect of small
doses (5U) of botulinum toxin A (BTA) injected directly into the painful
trigger points of the muscles.
Methods: 42 patients suffering from myofascial pain in the neck-shoulder
region were studied. The patients received either botulinum toxin A or
physiological saline injections on 3 occasions 6 weeks apart. The total dose
varied from 15 to 35 U of botulinum toxin A [27±4U (mean±SD)]. The
follow-up measurements were carried out at 6 weeks after each treatment.
Results: Neck pain values decreased from 5.1±1.9 to 3.1±1.8 after saline
injections and from 4.8±1.5 to 2.9±1.6 after botulinum toxin A. The
pressure pain threshold values increased from 5.4±1.7 to 5.8±1.2 and from
5.3±2.0 to 5.5±1.9 after injections with saline and botulinum toxin A,
respectively. No statistically significant changes in the neck pain and
pressure pain threshold values occurred between the botulinum toxin A and
saline groups. After the first injections, the subjective result of treatment
was significantly (P = 0.005) in favor of botulinum toxin A, and after
the second injections, the subjective result was better for saline, but
the difference was not statistically significant (P = 0.008). There was no
significant difference in the prevalence of side effects between saline and
botulinum toxin A.
Conclusions: Our study shows that there was no difference between the
effect of small doses of botulinum toxin A and those of physiological
saline in the treatment of myofascial pain syndrome.
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A LONG TERM FOLLOW UP OF PAIN, DEPRESSION AND
ANXIETY SYMPTOMS AMONG FIBROMYALGIA PATIENTS
E.A. Fors1 °, T. Landmark1, P.C. Borchgrevink1,2. 1Center for Pain
and Complex Disorders/St Olavs University Hospital, Trondheim,
Norway, 2Pain and Palliation Research Group, Department of Medicine,
Norwegian University of Science and Technology, Norway
Background and Aims: The objective of the present study was to investi-
gate the long term course of pain, depression and anxiety symptoms among
fibromyalgia (FMS) patients and to investigate the possible mediating roles
of age and education and on the course of pain.
Methods: A 14 year follow up of women being diagnosed with FMS
was conducted. Out of he original sample included 58 patients, 30 (52%)
agreed to participate in the follow up.
Self report instruments were used to examine changes in anxiety (STAI-T),
depression (BDI), and pain (100mm VAS) with General Linear Models,
Repeated Measures. Multiple linear regression were used to examine
possible influences of personality (MCMI-I), education and age on pain
change.
Results: The experience of pain remained fairly stable (VAS-
change = 2.72mm, p> 0.7) throughout the 14-year follow-up, while de-
pression (BDI) and anxiety (STAI-T) were significantly better (p< 0.02;
p< 0.001, respectively). No effects of age and level of education was
obtained. Follow up analyses showed that a subpopulation with significant
less pain (p< 0.001) after 14 years (n = 16) reported both less depression
(p< 0.05) and anxiety (p< 0.001), whereas a subpopulation with signifi-
cant more pain (p< 0.001, n = 14) reported reduction in anxiety (p = 0.012),
but not in depression (p = 0.205).
Conclusion: Women with FMS had stable pain measures through a
14 years follow-up study, while depression and anxiety diminished. For
a subpopulation with less pain, depression also improved, but when pain
increased, depression remained unchanged.
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BOTULINUM TOXIN A FOR MYOFASCIAL TRIGGER POINT
INJECTION: AN EVIDENCE-BASED SYSTEMATIC REVIEW
K.Y. Ho°, K.H. Tan. Department of Anaesthesia and Surgical Intensive
Care, Singapore General Hospital, Singapore
Background & Aim: Myofascial pain syndrome is a regional condition
of muscle pain and stiffness characterized by the presence of myofascial
trigger points. Botulinum toxin A (BTA) causes muscle paralysis by
blocking acetylcholine release at neuromuscular junctions. Its role in
trigger point injection remains debatable. The aim of this study was to
carry out a systematic review to assess the efficacy of BTA injection for
myofascial pain.
Methods: Search strategy: Electronic databases such as Medline,
Cochrane Library, Scopus, CINAHL were queried using key words such
as “botulinum toxin”, “myofascial pain”, “trigger point”, “chronic pain”
and “musculoskeletal pain”.
Selection criteria: Relevant published randomized controlled trials
(RCTs) that described the use of BTA as injection therapy for myofascial
pain were eligible for inclusion.
Data collection and analysis: Data extracted from qualified trials included
outcome measures such as pain intensity and pain pressure threshold.
Information on adverse effects was also extracted. All RCTs were ranked
according to the five-item 0–16 point Oxford Pain Validity Scale (OPVS).
Results: Five RCTs met the inclusion criteria. One trial concluded that
BTA was effective, and 4 concluded that it was not effective for treating
myofascial pain. OPVS scores ranged from 9 to 14 with negative studies
corresponding with higher validity scores.
Conclusion: The available evidence from the limited number of RCTs did
not support the use of BTA injection for treatment of myofascial pain.
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PAIN REPRESENTATION IN FIBROMYALGIA PATIENTS AND
HEALTHY CONTROLS USING EVENT-RELATED FMRI
K. Jensen1 °, E. Kosek1, T. Giesecke2, F. Petzke2, P. Fransson1,
S. Williams3, S. Carville3, E. Choy3, R. Gracely4, M. Ingvar1.
1Karolinska Institutet, Stockholm, Sweden, 2University Hospital of
Cologne, Cologne, Germany, 3Kings College Hospital, London, UK,
4University of Michigan, Ann Arbour, USA
The aim of this study was to compare the cerebral activations during
induced pressure pain in FMS patients and healthy controls. Pressure was
applied to the right thumbnail in 11 FMS patients and 11 healthy controls.
Analyses of cerebral activation showed increased activations in typical
pain-related structures. The only difference in brain activity was found in
Brodmann area 6 where healthy controls showed greater activity during
painful stimulation than FMS patients. In accordance to previous results
we found that subjective pain, representing significantly lower levels of
pressure in FMS patients, resulted in comparable activation patterns across
subject groups. This result supports the idea of augmented central pain
processing as a possible pathogenic component in FMS.
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AUTONOMIC NERVOUS SYSTEM ACTIVATION DURING
STATIC EXERCISE IN FIBROMYALGIA PATIENTS
D. Kadetoff1,2 °, E. Kosek1,3. 1Section of Clinical Pain Research,
Department of Molecular Medicine and Surgery, Karolinska Institute,
Stockholm Sweden, 2Department of Rehabilitation Medicine, Danderyds
Hospital, Stockholm, Sweden., 3Pain Center, Department of Neurosurgery,
Karolinska University Hospital, Stockholm, Sweden
Background: Basal sympathetic hyperactivity with hyporeactivity has
been reported in fibromyalgia (FM) patients. The aim of this study was to
